Please login to the form below
EU marketing authorisation
This page shows the latest EU marketing authorisation news and features for those working in and with pharma, biotech and healthcare.
EU announces agreement with Gilead for remdesivir supply
Drug was granted conditional marketing authorisation in the EU in July. ... The JPA replaces the initial deal funded by the EU’s emergency support instrument that ran from August through to October 2020.
Latest news
-
Bayer’s Vitrakvi scores first EU tumour-agnostic drug approval
The European Commission has given Vitrakvi conditional marketing authorisation in the EU for the treatment of adult and paediatric patients with solid tumours that display a NTRK gene fusion, which occurs ... The EU approval is good news for Bayer, as it
-
Time running out for ‘no-deal’ Brexit medicines laws
It says it will allow the parallel import of medicinal products that hold a marketing authorisation from an EU or EEA country, along with continuing to recognise prescriptions issued in EU ... UK to continue functioning should it have to leave the EU
-
Daily Brief: Andrew Witty's replacement on Accelerated Access initiative, Blincyto gains full EU approval and more
Blincyto gains full approval in Europe. Amgen’s leukemia treatment Blincyto, has been given full marketing authorisation in Europe, two years on from its first launch. ... The novel immunotherapy was first granted conditional marketing authorisation in
-
MSD launches EU’s first biosimilar Herceptin in UK
Ontruzant isn’t the only Herceptin biosimilar approved for marketing in Europe. ... Ontruzant was the fourth biosimilar developed by the Korean company to receive marketing authorisation in the EU, after Benepali (etanercept), Flixabi (infliximab), and
-
First Herceptin biosimilar cleared in Europe
Roche is claiming patent protection for Herceptin in the US out to 2019, but its EU patents expired in 2014. ... Ontruzant is the fourth biosimilar developed by the Korean company to receive marketing authorisation in the EU.
More from news
Approximately 1 fully matching, plus 56 partially matching documents found.
Latest Intelligence
-
Brexit implications for UK pharma legislation
require a significant increase in resourcing, met (mostly) by fees for assessing marketing authorisation applications and other services. ... Companies must be established in the EU to hold an EU/EEA marketing authorisation, and exports from the UK would
-
Shoring up the framework
Marketing authorisation holders for medicines, including orphan drugs, must be established in the EU or EEA. ... So for centrally authorised products the marketing authorisation holder will therefore normally need to transfer its marketing authorisation
-
Pharma deals during September 2012
Biotie will receive additional sales milestones on achievement of undisclosed sales target in Japan, increasing total reward to 89m ($120m). Lundbeck filed a marketing authorisation application for Selincro in the EU
-
Best practice in regulatory outsourcing: top tips
Holding a national or an EU Marketing Authorisation. Distribution that requires a licence (a Wholesale Dealers Licence and the services of a Responsible Person in the UK). ... Regulatory as a function has, in the past, been seen as the 'police' that says
More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
-
Healthcare Lead Copywriter
-
Competitive
- Sales Director, Healthcare communications agency, London/ SE UK
-
Six figure salary
-
Medical Editor
-
Competitive
-
Healthcare Senior Account Manager
-
Competitive
-
Healthcare Account Director
-
Competitive
- Account Manager Healthcare / Pharmaceutical Sector
-
Negotiable Salary
- GSK’s PD-1 inhibitor dostarlimab shows updated promise in dMMR solid tumours
- Moderna cooperating with investigation into possible COVID-19 vaccine allergic reactions
- Valneva set to begin commercial manufacturing of COVID-19 vaccine within days
- Sinovac’s COVID-19 vaccine appears safe in older adults
- Pfizer introduces new logo in a ‘shift from commerce to science’
- New study identifies drugs that are safe to use in COVID-19 treatment
- Mistrust in medical research: a patient perspective
- Real-world evidence: breaking boundaries in rare disease
- Live Webinar: Importance of Highlighting Patient Voices, Workforce Well-Being, and Health Literacy During and After the Pandemic
- The heavy toll of COVID-19 on cancer patients
- Unpacking rare diseases in the first edition of Delta magazine
- Virtual HealthTech conference powered by Impetus Digital: A Customer Story
PMHub
Branding Science
We are Branding Science Partners in thinking which inspires change in healthcare Branding Science are an award-winning global pharmaceutical market...
Latest intelligence
- Mistrust in medical research: a patient perspective
- The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...
- Real-world evidence: breaking boundaries in rare disease
- Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...
- The heavy toll of COVID-19 on cancer patients
- We all know that finding and treating cancer early saves lives. During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. So, what has been the impact of...
Quick links
Infographics
